scispace - formally typeset
Open AccessJournal Article

Long-term survival.

Cho Yw, +1 more
- 01 Jan 1988 - 
- pp 277
TLDR
In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year, and for patients receiving kidneys with no HLA-A,B mismatches, the average half- life was 10.1 years.
Abstract
1. In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year. Second cadaver donor grafts had a half-life of 5.1 to 6.5 years. Parental donor grafts had a half-life of 9.3 to 11.8 years, whereas HLA identical sibling donor transplants had a half-life of 19.1 to 26.5 years. Siblings with no haplotype in common had an average half-life of 8.7 years. 2. Between 1971 and 1984, white recipients had an average half-life of 7.7 years, which increased to 9.3 years in 1985-1986. Black recipients' half-life decreased from 5.4 years in 1975-1976 to 3.5 years in 1985-1986. The reason for this decrease is not apparent. 3. The half-life of transplants of different recipient ages did not vary significantly. The average half-life during this period of study was 7.4 years for those younger than 21 years of age, 8.2 years for recipients 21 to 50 and 6.7 years for those older than 50. 4. In the early data, there was some evidence that the half-life of kidneys with cold ischemia below 13 hours was superior. However, in the latest period (between 1983 and 1986) the average half-life was 7.6 years for CIT below 13 hours, 7.2 years for those with 13 to 24 hours and 6.4 years for more than 24 hours. 5. For patients receiving kidneys with no HLA-A,B mismatches, the average half-life was 10.1 years. Those with A,B mismatches had a half-life of 6.7 years, and for those with no A,B antigens in common, the average half-life was 6 years. 6. In the period after 1981, the average half-life of patients with no A,B,DR mismatches was 9.1 years compared with 6.5 years for those with A,B,DR mismatches and 5.4 years for those with no A,B,DR antigens in common.

read more

Citations
More filters
Journal ArticleDOI

The neurogenic bladder and incontinent urinary diversion.

TL;DR: Management of the neurogenic bladder with an incontinent stoma is necessary in situations in which intermittent catheterization via the urethra or a continentStoma is not feasible.
Journal ArticleDOI

Preoperative geriatric assessment: Comprehensive, multidisciplinary and proactive

TL;DR: A comprehensive, multidisciplinary and proactive preoperative assessment will be helpful to detect the multiple risk factors and comorbidities common in older patients, to assess functional status and simultaneously allow room for early preoperative interventions and planning of the intra- and postoperative period.
Journal ArticleDOI

Late endocrine, metabolic and skeletal sequelae following treatment of childhood cancer

TL;DR: In this review, the following potential problems are considered: growth hormone deficiency and replacement in adulthood, cardiovascular risk factors, osteopaenia, thyroid and parathyroid dysfunction.
Journal ArticleDOI

Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.

J Krebs, +1 more
- 01 Apr 2013 - 
TL;DR: Solifenacin treatment seems to be an effective oral treatment of NDO after SCI, and significantly improved bladder capacity, detrusor compliance, reflex volume and maximum detusor pressure.
Journal ArticleDOI

DNA-ploidy and survival in gastric carcinomas: a flow-cytometric study.

TL;DR: In 125 gastric carcinomas the nuclear DNA content was determined by flow cytometry from formalin-fixed and paraffin-embedded tissue of surgical specimens and DNA-aneuploidy was associated with a statistically significant poorer prognosis when compared to DNA-diploid tumours only in advanced gastric cancers with lymph node metastases.
Related Papers (5)
Trending Questions (1)
What is the biological half-life of the kidneys?

The biological half-life of kidneys varies based on donor type, recipient race, age, cold ischemia time, and HLA mismatches, ranging from 5.4 to 26.5 years in different scenarios.